TA50 Stock Overview
A clinical stage cancer immunotherapy and RNA therapeutics company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Circio Holding ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.14 |
| 52 Week High | kr1.95 |
| 52 Week Low | kr0.088 |
| Beta | 2.08 |
| 1 Month Change | -21.76% |
| 3 Month Change | -69.72% |
| 1 Year Change | -88.91% |
| 3 Year Change | -99.36% |
| 5 Year Change | -99.07% |
| Change since IPO | -99.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| TA50 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 42.0% | 0.5% | -0.3% |
| 1Y | -88.9% | -25.8% | 4.5% |
Return vs Industry: TA50 underperformed the German Biotechs industry which returned -25.8% over the past year.
Return vs Market: TA50 underperformed the German Market which returned 4.5% over the past year.
Price Volatility
| TA50 volatility | |
|---|---|
| TA50 Average Weekly Movement | 38.8% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: TA50's share price has been volatile over the past 3 months.
Volatility Over Time: TA50's weekly volatility has increased from 29% to 39% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 9 | Erik Wiklund | www.circio.com |
Circio Holding ASA, a clinical stage cancer immunotherapy and RNA therapeutics company. Its lead product candidate is ONCOS-102 for the treatment of mesothelioma and melanoma cancer. The company is also developing TG-01, a cancer vaccine program based on neoantigen vaccine for mutant KRAS cancers; and ONCOS immunotherapy technologies to stimulate the immune system.
Circio Holding ASA Fundamentals Summary
| TA50 fundamental statistics | |
|---|---|
| Market cap | €1.61m |
| Earnings (TTM) | -€9.55m |
| Revenue (TTM) | €10.61k |
151.7x
P/S Ratio-0.2x
P/E RatioIs TA50 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TA50 income statement (TTM) | |
|---|---|
| Revenue | kr123.00k |
| Cost of Revenue | kr0 |
| Gross Profit | kr123.00k |
| Other Expenses | kr110.86m |
| Earnings | -kr110.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | -13.35 |
| Gross Margin | 100.00% |
| Net Profit Margin | -90,029.27% |
| Debt/Equity Ratio | -114.9% |
How did TA50 perform over the long term?
See historical performance and comparison